Advertisement
Research ArticleArticle
Open Access

Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans

Terry Podoll, Paul G. Pearson, Jerry Evarts, Tim Ingallinera, Elena Bibikova, Hao Sun, Mark Gohdes, Kristen Cardinal, Mitesh Sanghvi and J. Greg Slatter
Drug Metabolism and Disposition February 2019, 47 (2) 145-154; DOI: https://doi.org/10.1124/dmd.118.084459
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

Bioavailability, Metabolism, and Excretion of [14C]Acalabrutinib

Terry Podoll, Paul G. Pearson, Jerry Evarts, Tim Ingallinera, Elena Bibikova, Hao Sun, Mark Gohdes, Kristen Cardinal, Mitesh Sanghvi and J. Greg Slatter
Drug Metabolism and Disposition February 1, 2019, 47 (2) 145-154; DOI: https://doi.org/10.1124/dmd.118.084459
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement